Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Operating Leases (2019 - 2025)

Puma Biotechnology's Operating Leases history spans 7 years, with the latest figure at $6.0 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 303.15% year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, up 303.15%, while the annual FY2025 figure was $6.0 million, 303.15% up from the prior year.
  • Operating Leases reached $6.0 million in Q4 2025 per PBYI's latest filing, down from $7.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $20.4 million in Q3 2021 to a low of $1.5 million in Q4 2024.
  • Average Operating Leases over 5 years is $11.4 million, with a median of $11.3 million recorded in 2022.
  • Peak YoY movement for Operating Leases: tumbled 78.76% in 2024, then skyrocketed 303.15% in 2025.
  • A 5-year view of Operating Leases shows it stood at $16.0 million in 2021, then decreased by 25.92% to $11.8 million in 2022, then crashed by 40.56% to $7.0 million in 2023, then crashed by 78.76% to $1.5 million in 2024, then skyrocketed by 303.15% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Operating Leases are $6.0 million (Q4 2025), $7.3 million (Q3 2025), and $4.4 million (Q2 2025).